Skip to main content
TETRATHERIX LIMITED logo

TETRATHERIX LIMITED — Investor Relations & Filings

Ticker · TTX ISIN · AU0000400574 ASX Manufacturing
Open in API
Filings indexed 66 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country AU Australia
Listing ASX TTX

About TETRATHERIX LIMITED

https://tetratherix.com/

Tetratherix Limited is a regenerative medicine company focused on the development of advanced synthetic scaffolds for bone and tissue repair. The company utilizes proprietary polymer technology to create biocompatible, resorbable materials that mimic the natural extracellular matrix, providing a structural framework for cellular attachment and tissue regeneration. Its primary product line includes synthetic bone graft substitutes designed for use in orthopedic, dental, and maxillofacial surgical procedures. These scaffolds are engineered with high porosity to facilitate vascularization and are gradually replaced by natural bone during the healing process. Tetratherix aims to provide clinical solutions that enhance the body's innate ability to repair complex bone voids and soft tissue defects through innovative material science.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 311.9KB
Regulatory Filings Classification · 85% confidence The document is an ASX market announcement notifying a trading halt at the company’s request under ASX Listing Rule 17.1, pending a material capital raising announcement. It does not present financial statements, investor presentation materials, nor detailed financing terms—rather, it is a regulatory announcement of a trading halt. Thus it falls under General Regulatory Filings (RNS).
2026-05-25 English
Quarterly Activities/Appendix 4C Cash Flow Report 16 pages 8.8MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 FY26 QUARTERLY ACTIVITIES REPORT' and is an ASX announcement dated April 23, 2026. It contains detailed business highlights, clinical trial updates, commercial agreements, manufacturing updates, and financial commentary including cash flow and payments to related parties. The content covers a specific quarter (Q3 FY26) and includes substantive financial data and operational analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements or substantive financial data and analysis. The document is not merely an announcement of a report but the report itself, and it is not a short summary or a certification. Therefore, the correct classification is IR with high confidence. Q3 2026
2026-04-22 English
Notification regarding unquoted securities - TTX 6 pages 18.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Tetratherix Limited. It includes specifics such as security codes, issue dates, and quantities issued. The content focuses on the notification of new securities issued, which aligns with announcements related to share issues or capital changes. There is no indication of financial statements, management discussion, or regulatory certifications. The document is a formal announcement of a share issue event, not a full report or financial statement. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2026-03-31 English
Tetratherix March Investor Presentation 35 pages 10.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Tetratherix Investor Presentation March 2026' and contains detailed descriptions of the company's technology platform, market opportunities, commercial model, R&D investments, and strategic positioning. It is structured as a presentation with multiple sections explaining the product, market trends, and business model. There are no financial statements, regulatory filings, or voting results. The content is typical of an investor presentation aimed at providing investors with an overview of the company's technology, strategy, and market potential. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-03-16 English
Precision medicine franchise launch and new revenue 4 pages 2.4MB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 16th March 2026 from Tetratherix Limited announcing a new precision medicine franchise, a partnership agreement with Superpower Health Inc, and expected revenue generation. It details the technology, the strategic partnership, expected milestones, and financial implications such as license payments and revenue streams. The document is a corporate announcement focused on business development, partnerships, and revenue updates rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial results, nor is it a transcript, proxy, or governance document. The content aligns with a Capital/Financing Update as it discusses new revenue streams, licensing agreements, and business expansion impacting the company's capital and financial outlook. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2026-03-15 English
Tutelix Update 4 pages 717.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 10th March 2026 announcing the progression of a clinical trial and the completion of a Series A capital raise by a joint venture partner. It discusses the clinical trial details, product differentiation, commercial opportunity, and future regulatory milestones. The document focuses on the capital raise and clinical trial progress rather than presenting financial results or detailed financial statements. There is no indication that this is a full annual or interim report, audit report, earnings release, or investor presentation. The primary content is an update on financing and clinical development progress, which fits best under Capital/Financing Update (CAP). The document length is about 9,844 characters, which is substantial but the content is clearly an announcement of capital raising and trial progress rather than a detailed financial report or presentation. Therefore, the most appropriate classification is CAP with high confidence.
2026-03-09 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.